Biotechnology

KIROMIC BIOPHARMA INC

KRBPQ.US released FY2024 Q4 earnings on February 14 (BJT) with actual revenue of 0 USD and EPS of 13.1344 USD

KRBPQ.US released FY2023 Q4 earnings on February 14 (BJT), with actual revenue of 0 USD and EPS of 3.167 USD

KRBPQ.US released FY2023 annual earnings on February 14 (BJT), with actual revenue of 0 USD and EPS of -12.588 USD

KRBPQ.US released FY2024 annual earnings on February 14 (BJT), with actual revenue of 0 USD and EPS of -3.1665 USD

KRBPQ.US released FY2024 Q3 earnings on November 8 (BJT), actual revenue 0 USD, actual EPS -6.1167 USD

KRBPQ.US released FY2024 9 Months Earnings on November 8 (BJT), with actual revenue of 0 USD and EPS of -17.1164 USD

KRBPQ.US released FY2023 9 Months Earnings on November 8 (BJT), with actual revenue of 0 USD and EPS of -17.432 USD

KRBPQ.US released FY2023 Q3 earnings on November 8 (BJT), with actual revenue of 0 USD and EPS of -4.2765 USD

KRBPQ.US released FY2024 semi-annual earnings on August 9 (BJT) with actual revenue of 0 USD and EPS of -11.0053 USD

KRBPQ.US released FY2023 Semi-Annual Earnings on August 9 (BJT), with actual revenue of 0 USD and EPS of -13.2254 USD

KRBPQ.US released FY2024 Q2 earnings on August 9 (BJT), with actual revenue of 0 USD and EPS of -5.5395 USD

KRBPQ.US released FY2023 Q2 earnings on August 9 (BJT), with actual revenue of 0 USD and EPS of -6.9858 USD

KRBPQ.US released FY2023 Q1 earnings on May 10 (BJT), actual revenue 0 USD, actual EPS -6.1696 USD

KRBPQ.US released FY2024 Q1 earnings on May 10 (BJT) with actual revenue of 0 USD and EPS of -5.4601 USD

KRBPQ.US released FY2022 annual earnings on March 19 (BJT), with actual revenue of 0 USD and EPS of -64.4213 USD

KRBPQ.US released FY2022 Q4 earnings on March 19, 2024 (BJT), with actual revenue of 0 USD and EPS of -11.7828 USD

Black Titan

AXIL Brands

Petmed Express

Agape ATP

Diamond Hill Investment

Mawson Infrastructure

SMX Security Matters

Nextdoor

Jiuzi

Planet Labs

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap